|
- Johnson Johnson: Changing health for humanity
Johnson Johnson MedTech innovates at the intersection of biology and technology With a focus on treating with pinpoint precision in the hardest-to-reach parts of the body, restoring anatomy and reimagining healing, our portfolio of smarter, less invasive, more personalized treatments is addressing the most complex diseases
- Pipeline - Innovative Medicine pipeline | Johnson Johnson - Investors
2025 Key events Major US EU approvals and submissions and phase 2 3 clinical data presentations being planned or achieved for the year Learn more
- Contact us - Johnson Johnson
Get in touch with Johnson Johnson You are now leaving jnj com The site you’re being redirected to is a branded pharmaceutical website
- Johnson Johnson Reports Q4 and Full-Year 2024 Results
NEW BRUNSWICK, N J --(BUSINESS WIRE)-- Johnson Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2024 "2024 was a transformative year for Johnson Johnson, marked by strong growth, an accelerating pipeline and industry-leading investments in innovation,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson Johnson
- Explore careers at Johnson Johnson | Johnson Johnson Careers
Elevate your career with J J Discover global job opportunities to drive innovation, impact lives and grow in a supportive, mission-driven culture
- J J global websites - Johnson Johnson
See all of Johnson Johnson's global website links
- Investor Relations | Johnson Johnson
The J J value At Johnson Johnson, we believe health is everything Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated and cured, treatments are smarter and less invasive and solutions are personal
- News and insights - Johnson Johnson
A collection of stories that highlight the way Johnson Johnson is making an impact in the lives of its consumers, and the latest press releases from the company
|
|
|